VIRULENCE will provide a strategy against a major health threat: occurrence of resistance against therapeutic HIV/AIDS-measures. Reverse transcriptase inhibitors play an essential role HIV -treatment RT variants with reduced susceptibility to these inhibitors emerge even under potent combination therapies and may become less virulent. Thus, emergence of RTI resistance negatively affects the inhibitor efficacy but may also result in virus variants with reduced pathogenicity. VIRULENCE aims at elucidating clinical consequences of changes in viral fitness for optimal use of antiviral drugs. VIRULENCE is first to address this through development and validation of improved fitness assays and their application on existing well-defined longitudinal clinical cohorts. The mol. mechanisms for viral fitness and resistance will be elucidated and new compounds active against drug resistant HIV will be defined. This integrated approach will improve care of patients with limited therapeutic options.
Funding SchemeCSC - Cost-sharing contracts
3000 Louvain / Leuven
OX3 7BN Oxford/headington